MV-NIS is an Edmonston lineage oncolytic measles virus expressing the human sodium iodide symporter-a means for monitoring by non-invasive imaging of radioiodine. Patients with relapsed, refractory myeloma who had explored all other treatment options were eligible for this Phase I trial. Cohort 1 was treated with intravenous MV-NIS, and Cohort 2 received cyclophosphamide 2 days prior to MV-NIS. Thirty-two patients were treated. Cohort 1 initially enrolled to four dose levels without reaching maximum tolerated dose (MTD) and subsequently to two higher dose levels when improved virus manufacture technology made it possible. MTD was not reached in Cohort 1, and TCID 50 10 11 is the dose being used in a Phase II trial of single agent MV-NIS. Grade 3-4 adverse events in both cohorts at all dose levels were: neutropenia (n = 9); leukocyte count decreased (n = 5); thrombocytopenia (n = 2); and CD4 lymphocytes decreased, anemia and lymphopenia (each n = 1). MV-N RNA sequences were amplified from gargle specimens, blood and urine. 123 I scans were positive in eight patients. One patient achieved a complete response; transient drops in serum free light chains were seen in other patients. MV-NIS is capable of replicating before being cleared by the immune system. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated myeloma.
INTRODUCTION
Multiple myeloma is not curable with current therapy and was expected to cause 11 240 deaths in the USA in 2015. 1 Median survival is~4 years and new approaches to therapy are urgently required. The disease responds initially to alkylating agents, immune modulators, proteasome inhibitors and corticosteroids, but eventually becomes refractory. New approaches are needed. Oncolytic immunotherapy is one such modality. 2, 3 Oncolytic viruses mediate their antitumor effects in two phases. Virusinfected tumor cells are killed during the oncolytic phase. Next uninfected tumor cells are killed by crossprimed tumor-specific cytotoxic T lymphocytes in immunotherapeutic phase.
MV-NIS is a live attenuated measles virus, engineered to express the human thyroidal sodium iodide symporter (NIS). 4, 5 The virus is selectively oncolytic, targeting and destroying tumor cells through CD46, a membrane regulator of complement activation that is known to be overexpressed on many human malignancies. [6] [7] [8] CD46 is the cellular receptor for MV-NIS, mediating both virus entry and subsequent cell killing through cell-cell fusion. 9 The CD46 tropism of attenuated Edmonston lineage measles viruses was acquired during tissue culture adaptation 10 and distinguishes them from wild-type measles viruses, which enter cells primarily through an alternative receptor, SLAM, expressed on activated T cells, B cells and monocytes 11 MV-NIS has dual tropism for both SLAM and CD46. The cytopathic effect of MV-NIS increases exponentially as the density of CD46 receptors on target cells increases and is therefore dramatic at high CD46 receptor densities (tumor), but minimal at low densities (normal tissues). 12 CD46 regulates complement activation by acting as a co-factor for factor I-mediated cleavage of C3b and thereby protects the cells on which it is expressed from complementmediated lysis. 6, 7 MV-NIS demonstrated considerable oncolytic potency when administered intravenously to rodents bearing human myeloma xenografts. 4, 5 Intratumoral spread of the virus was monitored non-invasively by radioiodine imaging and the anti-neoplastic potency of the virus was significantly boosted by 131 I.
Myeloma plasma cells overexpress CD46 and are, therefore, highly susceptible to MV-NIS. 13 We hypothesized that systemic virus administration would be feasible in patients with advanced myeloma, as these patients have greatly reduced circulating titers against common vaccine antigens such as measles. 14, 15 Cyclophosphamide was included as part of the treatment design to blunt too rapid and anamnestic response, which would be a threat to viral propagation and tumor targeting. 16, 17 It was our overall hypothesis that MV-NIS administered intravenously to patients with advanced multiple myeloma would selectively propagate in myeloma deposits throughout the body in a safe fashion. If this primary hypothesis was satisfied, this should lead to tumor cell killing and reduction of tumor burden, which could be tested in a Phase II setting. The primary hypothesis was tested in a Phase I clinical trial (NCT00450814) by serial qRT-PCR and nuclear imaging of radioiodine uptake after MV-NIS therapy to monitor the changing number and location of virusinfected cells.
MATERIALS AND METHODS Patients
Patients were eligible if they had relapsed or refractory myeloma, aged 18 years or older, at least two or more prior non-overlapping chemotherapeutic combinations but did not have known standard therapy known to extend life expectancy, ECOG performance status 0, 1 or 2, life expectancy of greater than 12 weeks, adequate bone marrow reserve (neutrophil count ⩾ 1 × 10 9 /l, platelets ⩾ 50 × 10 9 /l and hemoglobin ⩾ 8.5 g/dl), adequate organ reserve (AST ⩽ 2 times upper limit of normal, creatinine o2 times upper limit of normal, total bilirubin ⩽ 1.5 × upper limit of normal and an international normalized ratio ⩽ 1.4 × upper limit of normal), a negative serum pregnancy test done ⩽ 7 days prior to registration for women of childbearing potential, ability to provide written informed consent.
Patients were excluded if they had prior allogeneic stem cell transplantation, uncontrolled infection, chemotherapy within 3 weeks prior to registration, or immunotherapy or biologic therapy within 4 weeks of study registration, New York Heart Association classification III or IV, known symptomatic coronary artery disease, or known atrial fibrillation or superventricular tachycardia, active central nervous system disorders, HIVpositive test result, allergy to oral iodine, previous exposure to heatinactivated measles virus vaccine, pregnant or nursing women, men or woman with reproductive capacity not willing to use contraception and exposure to household contacts ⩽ 15 months old or household contact with known immunodeficiency.
Study oversight
This study was conducted in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the local human investigations committee. Written informed consent was obtained from all the patients before screening.
Study design
The primary goal of the Phase I trial was to determine the maximum tolerated dose (MTD) of MV-NIS when administered with or without cyclophosphamide in patients with relapsed or refractory multiple myeloma. Secondary end points included: (1) determination of the regimen's safety and toxicity profile; (2) hematologic response rate;
(3) time course of viral gene expression and virus elimination; (4) biodistribution of virally infected cells at various times points after infection with MV-NIS using 123 I nuclear imaging; (5) humoral responses to the injected virus.
The study consisted of two sequential dose escalation schemes to determine the MTD of MV-NIS when given with or without cyclophosphamide. First, patients were to be accrued to the prescribed dose levels for one dose of single agent MV-NIS. Once the MTD was determined for MV-NIS alone, then a second stage of dose escalation was to be done to determine the MTD of MV-NIS when given in combination with cyclophosphamide 10 mg/kg 2 days prior to the MV-NIS. The design was a standard 3+3 dose escalation, with a 6-week-observation window. When the trial began in 2006, the manufacturing capabilities of MV-NIS were limited to a maximum dose of TCID 50 of 10 9 ; therefore there were four dose levels in Stage I (no cyclophosphamide patients: TCID 50 10 6 , 10 7 , 10 8 and 10 9 ) and four dose levels in Stage II (with cyclophosphamide: MTD/100, 3 × MTD/ 100, 9 × MTD/100, 27 × MTD/100 and 81 × MTD/100). TCID 50 is defined as 50% tissue culture infective dose, which is the measure of infectious virus titer; more specifically, it quantifies the amount of virus required to produce a cytopathic effect in 50% of inoculated tissue culture cells. Due to new improved good manufacturing practices to produce higher titers of MV-NIS (Supplementary Methods), in October 2011, higher doses of MV-NIS could be produced, so Stage II was suspended after 21 patients had been accrued to it, and Stage I was reopened to evaluate dose levels 5 and 6, which were to deliver MV-NIS at TCID 50 , 10 10 and 10 11 ( Supplementary  Figure 1 ). Patients are notated in the results section by stage, dose level and patient number (that is, patient I.4.2 is Stage I, dose level 4, patient 2).
All patients with intact thyroid glands (that is, not previously surgically removed or ablated) received thyroid stimulating hormone suppressive doses of Cytomel orally (25 mcg three times daily) for 4 days prior to 123 I and through last dose required for imaging for the purpose reducing uptake of iodine by the thyroid gland by suppressing TSH-dependent expression of the NIS protein in the thyroid follicle, thereby recapitulating the anticipated biodistribution if therapeutic 131 I were to be used in a successor trial.
The virus was given at the inpatient Clinical Research Unit by infusion in 250 ml of normal saline over 30 min for the first 26 patients. When higher doses were reached, the infusion rate was slowed to 60 min due to infusion-related headache. Patients were closely monitored at the inpatient Clinical Research Unit during infusion of the virus for acute febrile reaction. Per protocol, patients who developed febrile responses to the infusion were treated with acetaminophen 650 mg by mouth and diphenhydramine hydrochloride 50 mg intravenously or by mouth. For rigors, meperidine hydrochloride 50 mg was administered by vein.
Dose-limiting toxicity (DLT) was defined as follows as any grade 3 or higher adverse events (AE) attributed to therapy with the following exceptions. Lymphopenia was not considered a DLT. Neutropenia was considered a DLT if it was grade 3 lasting more than 7 days or grade 4. Thrombocytopenia was considered a DLT only if it was grade 4 lasting more than 7 days. Symptomatic measles infection lasting 6 or more days, or a 10-fold increase in the measles N-gene RNA copy number (copies per microgram RNA) between sequential samples at least 3 days apart after day +15 were also part of the definition of DLT.
Study assessments
All patients underwent tumor assessments at baseline, including serum protein electrophoresis and quantitation immunoglobulin free light chains (FLC), magnetic resonance imaging, PET-CT and 123 I gamma camera imaging. All patients receiving a dose of drug were assessable for toxicity. All patients were assessed for hematologic response. Response was according to the IMWG response criteria. 18 Patients were educated about the symptoms of a measles-like illness (coryza, malaise, fever, rash, lymphadenopathy and transient suppression of the immune system) and were told to report these symptoms immediately. The protocol prescribed that treatment for measles with ribavirin and immune globulin be implemented if the symptoms (including temperature ⩾ 38.5°C) persist for as long as 6 days or earlier at the treating physician's discretion. The other contingency for instituting anti-viral therapy was a 10-fold increase in the copy number (copies per microgram RNA) between sequential samples at least 3 days apart after day +15. This increase beyond day 15 would be considered a DLT.
Laboratory correlates
Assessment of viremia and viral shedding. Mononuclear cells were isolated from blood, biopsy specimens, throat washings and urine according to protocol, and viral replication quantitative RT-PCR to determine virus RNA copy number was done. 19 Peripheral blood was collected in PAXgene tubes. Oral secretion samples were collected using Scope mouthwash. RNA was extracted using the Qiagen (Valencia, CA, USA) RNeasy Total RNA Kit and Qiagen QIAshredder. qRT-PCR was done using primers, the TaqMan One-step RT-PCR Master Mix Reagents Kit. (Applied Biosystems, Foster City, CA, USA), on a Stratagene MX4000 Multiplex Quantitative PCR System-a spectrophotometric thermocycler (Stratagene, LaJolla, CA, USA).
The description of the remaining laboratory correlates are contained in the Supplementary Materials.
Evaluation of MV-NIS biodistribution using SPECT/CT
Radioiodine uptake was visualized on SPECT/CT scans obtained 1-2 h after oral administration of 5 mCi 123 I. The scans were obtained at baseline and on days 8 and 15 post-virus administration using a Phillips Brightview SPECT/CT scanner (Cleveland, Oh, USA). To suppress thyroidal NIS Phase I MV-NIS expression, liothyronine sodium (25 mcg, three times daily) was administered orally for 4 days prior to the first scan and was continued until completion of the final scan. Those patients with a positive scan at day +15 had additional scans at day +22 and +29 until scans were negative. On day +8 dosimetry was done (day +8, 1-2 h post 123 I, day +8, 6 h post 123 I and day +9, which was 24 h post 123 I. Initial patients had gamma camera scans, but the protocol was amended to use SPECT-CT. The pre-scan and the '6 h scan' day 8 covered 80 cm of the body length (chest and abdomen); subsequent scans covered 40-80 cm (chest plus or minus abdomen) depending on regions of interest.
Data analysis AE were summarized including those events attributed to experimental agents. Exploratory analyses to identify predictors for response and correlations between viral persistence and baseline measures were performed using Fisher's exact test, Wilcoxon rank sum, Spearman ρ tests as appropriate. JMP 12.1 software was used (SAS, Carey, NC, USA).
RESULTS

Patients
Thirty-two patients were treated on the Phase I protocol. Three patients were replaced for lack of protocol completion. Baseline demographics for the 29 evaluable patients are shown in Table 1 . The median age of participants was 62 (range: 43-82). The median number of prior regimens was 5 (range: 2-15). Stage I initially enrolled 13 patients receiving one dose 10 6 , 10 7 , 10 8 or 10 9 TCID 50 of MV-NIS. Patient I.4.2 was replaced because he developed influenza pneumonia 4 days after treatment with MV-NIS. For the influenza pneumonia, he was hospitalized and unable to complete protocol assessments.
Because no DLT was observed at doses 10 6 , 10 7 , 10 8 or 10 9 TCID 50 , as per protocol, Stage 2, which included 10 mg/kg of cyclophosphamide 2 days prior to MV-NIS, began to accrue patients ( Supplementary Figure 1) . Eight patients were enrolled receiving doses of TCID 50 10 7 , 3×10 7 and 9 × 10 7 . At trial conception, manufacturing allowed doses only up to 10 9 TCID 50 , but technology improvements subsequently allowed for two higher dose levels (10 10 and 10 11 TCID 50 ). Therefore, Stage II accrual was suspended, and Stage I accrual was resumed to test these two higher levels. Four patients received 10 10 and 7 patients received 10 11 . Patient I.5.3 was replaced because of the inability to follow through an trial follow-up due to rapidly progressive myeloma. Patient I.6.1 was replaced because one-tenth of the expected dose was administered due to infusion reaction (headache). One patient experienced a DLT on dose level 6 (patient I.6.7, neutrophils). In Stage I, MTD was not reached, and TCID 50 10 11 was deemed the treatment dose for Phase II study. Accrual to Stage II (with cyclophosphamide) remains suspended such that single agent MV-NIS could be more formally assessed as a Phase II trial. Table 2 and Supplementary Table 1 summarize the frequency of AE deemed to be at least possibly related to MV-NIS therapy in the 29 evaluable patients. Grade 1-2 AEs seen in at least five patients were: nausea (n = 10); chills (n = 9); leukopenia (n = 8); fever (n = 7); and diarrhea and neutropenia, (each n = 5). Grade 3-4 AEs deemed at least possibly related to protocol therapy in both cohorts at all dose levels were: neutropenia (n = 9); leukocyte count decreased (n = 5); thrombocytopenia (n = 2); and CD4 lymphocytes decreased, anemia and lymphopenia (each n = 1). One patient treated in Cohort 2, dose level 3 (for example, CTX and TCID 50 9 × 10 7 ) had a grade 3 left ventricular failure possibly related to therapy.
Adverse events
Measles immunity pre-and post treatment Pre-existing and post-therapy measles virus immunity was tested using two methods. By enzyme-linked immunosorbent assay (ELISA) and neutralizing assay titer, 10 of 31 and 13 of the 31 patients had pre-existing measles immunity (Figure 1 ; Supplementary Table 2 ). Post treatment 25 of 27 and 27 of 27 were measles positive by ELISA and neutralizing antibody, respectively. Table 2 ). As shown in Supplementary Figure 2A , the CD138-positive cells were more easily infected than the CD138-negative cells with respective median (range) of 52% (43%, 63%) versus 5% (1%, 18%). The CD138-positive cells expressed significantly higher numbers of surface CD46 molecules than the CD138-negative cells (Supplementary Figure 2B) . Pharmacokinetics/pharmacodynamics Serial measurements of blood N-gene were performed in the first 4 h of therapy in patients II.1.2 onward (Figure 2 ). Virus cleared from blood by 4 h for patients receiving o 10 8 even when administered with CTX. For two of the three patients receiving TCID 50 10 9 , N-gene was measurable up through day 3 but not beyond. Once patients were treated with doses of TCID 50 10 11 , N-gene was detected in 2 of 4 patients at day 8 and 1 of 4 at day 15 and the highest peaks were achieved in those patients given this highest dose.
Assessment of baseline bone marrow's infectivity ex vivo Twenty patients had enough bone marrow to perform ex vivo infectivity experiments (Supplementary
No patients treated with doses below TCID 50 10 9 had persistent viremia detected at 72 h (Figures 2 and 3) . All but two patients (I.4.1 and I.5.4) treated with TCID 50 10 9 or higher had persistent viremia detected at 72 h; these two patients had positive MV titers at baseline. Their respective ELISA titers were 40.4 and 77.8, and In contrast to detectable N-gene in the blood being present only at the highest dosing levels, detection of viral genomes in the sputum at the TCID 50 10 6 and 10 7 levels at days 8, 15 and 22 was sporadic (Figure 3) . At TCID 50 10 9 and higher dosing viral genome was detected in the sputum in the majority of patients. Quite similarly, in the urine, genome was sporadically present in the urine with doses of less than TCID 50 10 11 , but in all cases at doses of TCID 50 10 11 .
Additional baseline and 6-week-post-therapy correlative results are shown in Supplementary Table 1 . Predictors for persistent viremia were sought. There was an inverse correlation between Stage II   DL1  DL2  DL3  DL4  DL5  DL6 a  DL1  DL2  DL3   Grade  1  2  1  2  3  1  2  3  1  2  1  2  3  1  2  3  4  1  2  3  1  2  3  1 Phase I MV-NIS baseline T cells (both CD4 and CD8) and viremia at day 22 (ρ = − 0.7080, P = 0.01 and ρ = − 0.7251, P = 0.0076, respectively). Baseline anti-measles titers either by ELISA or by neutralizing antibody assay were not associated with duration of viremia or level of viremia in either the full data set or the smaller subset of patients treated at the higher levels, though this may be limited by the fact that the majority of patients had very low titers.
Response
There was one major hematologic response as has been reported previously. 20 Patient I.6.3, who was treated at TCID 50 10 11 , achieved a complete response that persisted for 9 months; she had isolated relapse in her skull without recurrent marrow involvement. This lesion was irradiated, and she remained disease free for an additional 19 months thereafter at which time she had a second isolated relapse in her sternum. Four other patients had transient reductions in their serum immunoglobulin FLC of at least 25% during the first 4 weeks of therapy (Figure 4 ), one of whom was treated with cyclophosphamide and MV-NIS at TCID 50 of 9 × 10 7 , and the remainder who were treated with single agent MV-NIS. One of these patients, I.6.6, had subjective softening and shrinking of her extramedullary plasmacytomas of her back and thighs.
Whether one focuses on the 11 patients treated at TCID 50 10 10 or higher or all 32 participants, those patients with a 25% difference of involved and uninvolved free light chains reduction tended to have bone marrow plasma cells with lower levels of CD46 and higher levels of SLAM expression (Table 3) . Surprisingly there was no difference in the baseline measles titers either by ELISA or by neutralizing antibodies. The ex vivo testing of measles infectivity at baseline was not informative in the FLC reduction group as only one patient had enough bone marrow plasma cells to perform the experiment (Patient I.5.4). His infectivity was 53%, which was comparable to that of the other 19 patients who had the assay performed but no reductions in FLC.
Correlative studies
There was no correlation between baseline CD46 density or SLAM density on the bone marrow plasma cells or non-plasma cells, and ex vivo infectivity by MV nor was there any correlation between baseline CD46 density or SLAM density and persistent viremia at day 8 or 15. However, CD46 density was, in all cases, higher on the neoplastic plasma cells compared to non-plasma cells and this was correlated with their higher susceptibility to MV infection. There was a relationship between the quantity of CD8 (suppressor T cells) in the peripheral blood and the ex vivo infectivity of the CD138+ bone marrow cells (ρ = 0.6233, P = 0.0044). None of the baseline characteristics (numbers of peripheral blood T cells, B cells or NK cells) predicted for high viral titers at day 15 in the overall data set except for pharmacokinetics at 60 min (ρ = 0.70, P = 0.002).
Imaging
Of the 31 patients, 8 had some degree of 123 I uptake on their SPECT/CT scans. Three were in the Stage 2 group, that is, they Figure 2 . Summary of pharmacokinetics and correlative studies by dose level. The infusion rate of virus was 100 ml over 30 min for all patients through patient I.5.4. For patients I.6.1-I.6.3, the intent was the same, but at this dose of virus, actual infusion rates were 85, 156 and 99 min, respectively, due to infusion reactions (see text) requiring halting and resumption of drug. Patient I.6.1 received only 11 ml of drug due to infusion reaction, and was therefore replaced. Thereafter, the protocol was modified to a 250 ml over 2.5 h in for patients I.6.4-I.6.6. The infusion rate for patient I. received CTX pre-MV-NIS. Four of the other five positive patients were treated at TCID 50 10 10 or higher. In most patients, not all lesions had uptake, and uptake was modest. An example of a 123 I scan was seen in participant I.6.6 ( Figure 5 ). We could identify no baseline features predicted for positive 123 I SPECT/CT scans.
DISCUSSION
Herein, we describe a completed Phase I trial using a modified measles virus through an intravenous route for disseminated malignancy. We have demonstrated systemic administration of MV-NIS in patients with myeloma may be a safe and novel approach to salvage patients with multiply relapsed and refractory disease. Even at the highest doses, MV-NIS was reasonably well tolerated with the exception of significant infusion reactions (fever, chills and gastrointestinal upset) proximal to the therapy. We found that infusion of TCID 50 10 11 was not practical over 30 min, predominantly due to headache, but is better tolerated with a less rapid infusion. The most significant AE's at the Phase II recommended dose level (TCID 50 10 11 ) were short-lived constitutional and gastrointestinal symptoms along with transient cytopenias.
We collected a large amount of data on our subjects, which is informative for the Phase II trial. First, there was a clear dose response in terms of higher blood stream levels achieved and more sustained viremia with higher doses infused. Viral shedding in the sputum and urine was typically limited to the first 8-15 days after therapy. In fact, among the 11 patients treated at TCID 50 10 10 or greater, there were 3 transient FLC responses and 1 durable hematological response. Second, undetectable measles titers are found in 58-68% of patients with multiply relapsed myeloma. Although the patient who had the dramatic hematologic response had undetectable measles virus titers and prolonged viremia, there was no clear pattern of negative baseline measles titers or persistent viremia among the other four patients with transient dFLC responses.
Neither ex vivo infectivity experiments nor CD46 expression on the bone marrow plasma cells predicted for transient response, levels of viremia or positive 123 I scans. Any conclusions, however, about the predictive value of these correlates are limited by the small sample size of patients treated at the recommended Phase II dose. These parameters will be explored further in the Phase II.
The relative safety of this drug, the one dramatic response and the four transient responses make future study possible and hopefully fruitful. If single agent MV-NIS does not prove to be as Phase I MV-NIS effective as hoped, there are several potential strategies available. Preliminary data demonstrate that infecting mesenchymal cells with MV-NIS and using them as carriers allow the virus to evade the immune system more effectively. 21 Use of combination therapy with immune modulating drugs such as high-dose cyclophosphamide or with immune check-point inhibitors is also another potential strategy to enhance efficacy of this novel agent. 17 Assuming one can achieve a more predictable and robust NISmediated radioisotope enhancement, using therapeutic 131 I along with the MN-NIS may also be an option for enhancing tumor kill. 5 Abbreviations: BMPC, bone marrow plasma cells; FLC, free light chains; MFI, mean fluorescent intensity; qRT, quantitative real-time; NS, not significant . a Stage I patients at TCID50 10 10 and 10 11 . b Comparator of '25% FLC reduction' group includes five patients, i.e., the four patients treated at 10 11 TCID 50 or higher and the one Stage II patient treated with CTX and only 10 7 TCID 50 . 
